Form 8-K - Current report:
SEC Accession No. 0001193125-24-272442
Filing Date
2024-12-06
Accepted
2024-12-06 16:04:29
Documents
15
Period of Report
2024-12-02
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d829648d8k.htm   iXBRL 8-K 30694
2 EX-99.1 d829648dex991.htm EX-99.1 13236
6 GRAPHIC g829648g1205081104035.jpg GRAPHIC 6348
  Complete submission text file 0001193125-24-272442.txt   186834

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vinc-20241202.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20241202_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20241202_pre.xml EX-101.PRE 11699
17 EXTRACTED XBRL INSTANCE DOCUMENT d829648d8k_htm.xml XML 3767
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 241532235
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)